In the last trading session, 1.15 million NewAmsterdam Pharma Company NV (NASDAQ:NAMS) shares changed hands as the company’s beta touched -0.02. With the company’s per share price at $18.11 changed hands at -$0.46 or -2.48% during last session, the market valuation stood at $2.03B. NAMS’s last price was a discount, traded about -50.69% off its 52-week high of $27.29. The share price had its 52-week low at $14.06, which suggests the last value was 22.36% up since then. When we look at NewAmsterdam Pharma Company NV’s average trading volume, we note the 10-day average is 1.09 million shares, with the 3-month average coming to 894.64K.
Analysts gave the NewAmsterdam Pharma Company NV (NAMS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NAMS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. NewAmsterdam Pharma Company NV’s EPS for the current quarter is expected to be -0.43.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
Instantly NAMS was in red as seen at the end of in last trading. With action -0.55%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -8.30%, with the 5-day performance at -0.55% in the red. However, in the 30-day time frame, NewAmsterdam Pharma Company NV (NASDAQ:NAMS) is 2.72% up. Looking at the short shares, we see there were 6.97 million shares sold at short interest cover period of 8.99 days.
The consensus price target for the stock as assigned by Wall Street analysts is 41, meaning bulls need an upside of 55.83% from its current market value. According to analyst projections, NAMS’s forecast low is 41 with 41 as the target high. To hit the forecast high, the stock’s price needs a -126.39% plunge from its current level, while the stock would need to soar -126.39% for it to hit the projected low.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
Year-over-year growth is forecast to reach -59.53% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 1.54M. 12 analysts are of the opinion that NewAmsterdam Pharma Company NV’s revenue for the current quarter will be 5.75M. The company’s revenue for the corresponding quarters a year ago was 2.08M and 27.13M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -25.90%. The estimates for the next quarter sales put growth at -78.82%.
The 2025 estimates are for NewAmsterdam Pharma Company NV earnings to increase by 30.96%, but the outlook for the next 5-year period is at 13.98% per year.
NAMS Dividends
NewAmsterdam Pharma Company NV is expected to release its next quarterly earnings report on 2025-May-08.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.39% of NewAmsterdam Pharma Company NV shares while 112.95% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 113.38%. There are 112.95% institutions holding the NewAmsterdam Pharma Company NV stock share, with FRAZIER LIFE SCIENCES MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 12.9097% of the shares, roughly 12.23 million NAMS shares worth $234.88 million.
FCPM III SERVICES B.V. holds the second largest percentage of outstanding shares, with 12.4921% or 11.83 million shares worth $227.28 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were SMALLCAP WORLD FUND INC and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . With 6.65 shares estimated at $120.41 million under it, the former controlled 5.92% of total outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held about 1.92% of the shares, roughly 2.16 shares worth around $39.05 million.
